Cargando…

An optimal stratified Simon two‐stage design

In Phase II oncology trials, therapies are increasingly being evaluated for their effectiveness in specific populations of interest. Such targeted trials require designs that allow for stratification based on the participants' molecular characterisation. A targeted design proposed by Jones and...

Descripción completa

Detalles Bibliográficos
Autores principales: Parashar, Deepak, Bowden, Jack, Starr, Colin, Wernisch, Lorenz, Mander, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405342/
https://www.ncbi.nlm.nih.gov/pubmed/26932771
http://dx.doi.org/10.1002/pst.1742
_version_ 1783231745957560320
author Parashar, Deepak
Bowden, Jack
Starr, Colin
Wernisch, Lorenz
Mander, Adrian
author_facet Parashar, Deepak
Bowden, Jack
Starr, Colin
Wernisch, Lorenz
Mander, Adrian
author_sort Parashar, Deepak
collection PubMed
description In Phase II oncology trials, therapies are increasingly being evaluated for their effectiveness in specific populations of interest. Such targeted trials require designs that allow for stratification based on the participants' molecular characterisation. A targeted design proposed by Jones and Holmgren (JH) Jones CL, Holmgren E: ‘An adaptive Simon two‐stage design for phase 2 studies of targeted therapies’, Contemporary Clinical Trials 28 (2007) 654‐661.determines whether a drug only has activity in a disease sub‐population or in the wider disease population. Their adaptive design uses results from a single interim analysis to decide whether to enrich the study population with a subgroup or not; it is based on two parallel Simon two‐stage designs. We study the JH design in detail and extend it by providing a few alternative ways to control the familywise error rate, in the weak sense as well as the strong sense. We also introduce a novel optimal design by minimising the expected sample size. Our extended design contributes to the much needed framework for conducting Phase II trials in stratified medicine. © 2016 The Authors Pharmaceutical Statistics Published by John Wiley & Sons Ltd
format Online
Article
Text
id pubmed-5405342
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54053422017-04-26 An optimal stratified Simon two‐stage design Parashar, Deepak Bowden, Jack Starr, Colin Wernisch, Lorenz Mander, Adrian Pharm Stat Main Papers In Phase II oncology trials, therapies are increasingly being evaluated for their effectiveness in specific populations of interest. Such targeted trials require designs that allow for stratification based on the participants' molecular characterisation. A targeted design proposed by Jones and Holmgren (JH) Jones CL, Holmgren E: ‘An adaptive Simon two‐stage design for phase 2 studies of targeted therapies’, Contemporary Clinical Trials 28 (2007) 654‐661.determines whether a drug only has activity in a disease sub‐population or in the wider disease population. Their adaptive design uses results from a single interim analysis to decide whether to enrich the study population with a subgroup or not; it is based on two parallel Simon two‐stage designs. We study the JH design in detail and extend it by providing a few alternative ways to control the familywise error rate, in the weak sense as well as the strong sense. We also introduce a novel optimal design by minimising the expected sample size. Our extended design contributes to the much needed framework for conducting Phase II trials in stratified medicine. © 2016 The Authors Pharmaceutical Statistics Published by John Wiley & Sons Ltd John Wiley and Sons Inc. 2016-03-02 2016 /pmc/articles/PMC5405342/ /pubmed/26932771 http://dx.doi.org/10.1002/pst.1742 Text en © 2016 The Authors Pharmaceutical Statistics Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Main Papers
Parashar, Deepak
Bowden, Jack
Starr, Colin
Wernisch, Lorenz
Mander, Adrian
An optimal stratified Simon two‐stage design
title An optimal stratified Simon two‐stage design
title_full An optimal stratified Simon two‐stage design
title_fullStr An optimal stratified Simon two‐stage design
title_full_unstemmed An optimal stratified Simon two‐stage design
title_short An optimal stratified Simon two‐stage design
title_sort optimal stratified simon two‐stage design
topic Main Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405342/
https://www.ncbi.nlm.nih.gov/pubmed/26932771
http://dx.doi.org/10.1002/pst.1742
work_keys_str_mv AT parashardeepak anoptimalstratifiedsimontwostagedesign
AT bowdenjack anoptimalstratifiedsimontwostagedesign
AT starrcolin anoptimalstratifiedsimontwostagedesign
AT wernischlorenz anoptimalstratifiedsimontwostagedesign
AT manderadrian anoptimalstratifiedsimontwostagedesign
AT parashardeepak optimalstratifiedsimontwostagedesign
AT bowdenjack optimalstratifiedsimontwostagedesign
AT starrcolin optimalstratifiedsimontwostagedesign
AT wernischlorenz optimalstratifiedsimontwostagedesign
AT manderadrian optimalstratifiedsimontwostagedesign